Skip to main navigation
Syndax
Main navigation
  • About
    • Back
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Vision, Mission, and Values
  • Pipeline
    • Back
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Back
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • Back
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Back
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Back
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Back
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Back
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • FAQs
    • Contact Us
  • Join Us
Syndax
Contact Us
Main navigation
  • About
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Vision, Mission, and Values
  • Pipeline
    • Pipeline Overview
    • Revumenib
    • Axatilimab
    • Entinostat
    • Publications & Meeting Presentations
  • Clinical Trials
    • Clinical Trials Overview
    • Revumenib Clinical Trials
      • AUGMENT-101 (monotherapy)
      • AUGMENT-102 (chemo combo)
    • Axatilimab Clinical Trials
    • Compassionate Use
  • Patients & Caregivers
  • Investors
    • Investors Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • Financial Overview
      • SEC Filings
      • Annual Reports and Proxies
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Stock Overview
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • FAQs
    • Contact Us
  • Join Us

Investors

 

Press Releases

06.06.07

FierceBiotech Names Syndax Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2007

04.13.07

Syndax Pharmaceuticals Inc. Licenses Selective Histone Deacetylase Inhibitor MS-275

04.03.07

Syndax Pharmaceuticals Inc. closes $40 Million Series A Financing

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Current page 22

Shareholder Tools

  • Printed Materials
  • Downloads
  • Email Alerts
  • RSS
  • Print
  • Share
  • Search

  • Facebook
  • Google
  • LinkedIn
  • Twitter
  • RSS
© 2023 Syndax | Terms of Use | Privacy Policy | Site Map
  • About Us
  • Pipeline
  • News
  • Investors
  • Careers